PRO HMPV+ ASSAY

K132200 · Gen-Probe Prodesse, Inc. · OEM · Aug 14, 2013 · Microbiology

Device Facts

• Record ID: K132200
• Device Name: PRO HMPV+ ASSAY
• Applicant: Gen-Probe Prodesse, Inc.
• Product Code: OEM · Microbiology
• Decision Date: Aug 14, 2013
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 866.3980
• Device Class: Class 2

Indications for Use

The Prodesse® Pro hMPV®+ Assay is a Real-Time PCR (RT-PCR) in vitro diagnostic test for the qualitative detection of human Metapneumovirus (hMPV) nucleic acid isolated and purified from nasopharyngeal swab (NP) specimens obtained from individuals exhibiting signs and symptoms of acute respiratory infection. This Assay targets a highly conserved region of the Nucleocapsid gene of hMPV. The detection of hMPV nucleic acid from symptomatic patients aids in the diagnosis of human respiratory hMPV infection if used in conjunction with other clinical and laboratory findings. This test is not intended to differentiate the four genetic sublineages of hMPV. Negative results do not prectude hMPV infection and should not be used as the sole basis for diagnosis, treatment or other management decisions.

Device Story

Real-time RT-PCR assay for qualitative detection of human Metapneumovirus (hMPV) nucleic acid; targets conserved Nucleocapsid gene region. Input: nasopharyngeal swab specimens in viral transport medium. Process: nucleic acid isolation/purification via MagNA Pure LC or NucliSENS easyMAG; reverse transcription and amplification using Pro hMPV+ Supermix and enzymes; Taqman chemistry with FAM-labeled probe for hMPV and Quasar 670-labeled probe for Universal Internal Control (UIC). Output: fluorescent signal intensity monitored by Cepheid SmartCycler II instrument. Used in clinical laboratory settings by trained personnel. Results aid diagnosis of respiratory infection when combined with other clinical/laboratory findings.

Clinical Evidence

Retrospective clinical comparison study demonstrated that the modified assay with Universal Internal Control (UIC) maintains performance claims equivalent to the previous version of the device. Analytical studies (sensitivity, IC interference, extractor equivalency, sample stability) confirmed functionality.

Technological Characteristics

Real-time RT-PCR assay; Taqman chemistry; FAM/Quasar 670 fluorophores. Targets Nucleocapsid gene. Requires external instrumentation (MagNA Pure LC or NucliSENS easyMAG for extraction; Cepheid SmartCycler II for amplification/detection). Includes Universal Internal Control (RNA/DNA).

Indications for Use

Indicated for qualitative detection of human metapneumovirus (hMPV) RNA in nasopharyngeal swab specimens from patients with respiratory infection symptoms. Intended for use by professional laboratory personnel to aid in diagnosis.

Regulatory Classification

Identification

A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses:(1) Influenza A and Influenza B; (2) Influenza A subtype H1 and Influenza A subtype H3; (3) Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B; (4) Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus; (5) Human Metapneumovirus; (6) Rhinovirus; and (7) Adenovirus.

Special Controls

*Classification.* Class II (special controls). The special controls are:(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;” (2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and (3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents.

Predicate Devices

• Prodesse® Pro hMPV+ Assay (K123838)

Submission Summary (Full Text)

{0}

SPECIAL 510(k): Device Modification Review Memorandum

To: Hologic, Inc. (Gen-Probe Prodesse, Inc.)

RE: K132200

This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II devices requiring 510(k). The following items are present and acceptable:

1. The name and 510(k) number of the SUBMITTER'S previously cleared device:

Prodesse® Pro hMPV™+ Assay

510(k) number: K123838

2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use and package labeling.

3. A description of the device MODIFICATION(S) to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed.

The 510k submission contained modifications to the Internal Control.

a. Incorporation of a Universal Internal Control that contains a RNA in vitro transcript (IVT) and a DNA plasmid;

The current Internal Control (RIC) in Pro hMPV+ Assay contains a RNA in vitro transcript (IVT). The new Universal Internal Control (UIC-A) will contain a RNA in vitro transcript (IVT) and a DNA plasmid to allow users to perform one nucleic acid extraction and test with any combination of the Pro+ Series Assays including ProFlu+, ProhMPV+, ProParaflu+, ProFAST+, and ProAdeno+. The concentration of the RNA IVT in the Universal Internal Control (UIC-A) is the same as in the current Internal RNA Control (RIC). Handling of Universal Internal Control is identical to that of the current Internal RNA Control (RIC) included in the Pro hMPV + Assay.

b. Outsourcing of the manufacturing of the Internal Control and subsequent minor sequence changes.

Due to the different vector being used in the Universal Internal Control (UIC-A), minor changes were made to the 5' and 3' ends of the UIC-A sequence.

4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, and physical characteristics.

| Element | Similarities | |
| --- | --- | --- |
| | Modified Prodesse Pro hMPV+ Assay | Current Prodesse Pro hMPV+ Assay (K123838) |
| Organisms Detected | Same | Human metapneumovirus |
| Analyte | Same | RNA |
| Technological Principles | Same | Multiplex nucleic acid amplification |
| Specimen Types | Same | Nasopharyngeal Swab |
| User Complexity | Same | High |
| Sample Preparation Method | Same | Up front sample processing is required to extract nucleic acid. |

{1}

Page 2 of 4

| Instrumentation | Same | bioMérieux NucliSENS easyMAG or Roche MagNA Pure and Cepheid SmartCycler II Instrument |
| --- | --- | --- |
| Time to result | Same | Approximately 4 hours |
| Controls | Same | Internal control in each sample.
External control processed with each batch of samples.
Positive Control is provided at “at use” concentration. |
| Differences | | | |
| --- | --- | --- | --- |
| Element | | Modified Pro hMPV+ Assay | Current Prodesse Pro hMPV+ Assay |
| Controls | Internal | • Universal Internal Control
- Contains DNA plasmid in addition to RNA IVT
• Control Stocks outsourced
- Change in manufacturer leading to a change in control vector and minor sequence change at the 5' and 3' ends of RNA IVT | • Internal RNA Control
- Contains RNA IVT
• Control stocks manufactured in house |

# 5. A Design Control Activities Summary:

a. Identification of Risk Analysis method used to assess the impact of the modification on the device and its components, and the results of the analysis;

FMEA was performed to determine whether the current design changes create new risks or failure modes or affect the risk priority number (RPN) value. No additional risk or change in RPN value was identified in the Risk Analysis.

b. To demonstrate that the modifications in Internal Control do not change the assay performance, Analytical Studies and a Comparison Study were conducted.

- Analytical Performances:

- Analytical Sensitivity Confirmation

LoD, which was established in K123838 in 2013, was confirmed for hMPV using one strain of virus when tested with the UIC-A control side by side with the current RIC control. The LoD was confirmed to be at $1 \times 10^{0.5} \mathrm{TCID}_{50} / \mathrm{mL}$.

- IC Interference Study

The IC Interference Study demonstrated that the new control, UIC-A, did not inhibit the detection of target organisms at levels close to LoD.

- Sample Stability Study

The study demonstrated that the stability of the samples would not be affected by a change in the internal control.

- Extractor Equivalency Studies

The study for equivalency of nucleic acid extraction methods between the bioMérieux NucliSENS easyMAG automated extractor and Roche MagNA Pure LC extractor demonstrated the equivalency between the two extraction methods.

{2}

Page 3 of 4

- Comparison Study:

The comparison study was conducted for all Pro+ Series Assays including ProFlu+, Pro hMPV+, ProParaflu+, ProFAST+, and ProAdeno+ using 366 positive samples and 66 negative samples. Among the 366 positive samples, 330 were retrospective pre-selected archived NPS specimens with 30 positive samples per target (11 targets total) and 36 were contrived samples, generated by spiking individual negative retrospective NPS samples with whole organism (Influenza A/Seasonal H1 or Parainfluenza 2). Each sample was split into 3 aliquots; one aliquot was tested using the current Internal RNA Control (RIC), one aliquot was tested using the Universal Internal Control (UIC-A), and one aliquot was tested using the current Universal Internal Control (UIA-P) for ProAdeno+ Assay. All samples were then split into 72 panels with 6 samples per panel, extracted and tested by four different operators. Half of the panel samples were extracted using the bioMérieux NucliSENS easyMAG method and the other half using the Roche MagNA Pure LC method. Of the 432 samples utilized in the study, 19 samples were removed from analysis due to the invalid controls or incomplete test results. The results for the Pro hMPV+ Assay are summarized in the following table:

| Pro hMPV+ Assay Results | | | | | |
| --- | --- | --- | --- | --- | --- |
| | | Samples with RIC | | | |
| Samples with UIC-A | | Positive | Negative | Total | Comments |
| | Positive | 30 | 0 | 30 | Percent Positive Agreement 100% (88.7% - 100%) 95% CI |
| | Negative | 0 | 383 | 383 | Percent Negative Agreement 100% (99.0% - 100%) 95% CI |
| Total | | 117 | 383 | 413 | |

The results of analytical studies and the clinical study confirmed the original performance claims of the Pro hMPV+ Assay and demonstrated that assay performance was not affected by the incorporation of the new Universal Internal Control (UIC-A). The Pro hMPV+ Assay package insert has been updated to reflect the changes in the internal control.

c. A declaration of conformity with design controls was submitted for the manufacturing facility which includes:

i) A statement signed by the Senior Director of R & D, Gen-Probe Prodesse, Inc., was submitted confirming that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met, and
ii) A "Declaration of Conformity" statement signed by the Associate Director of Quality and Regulatory, Gen-Probe Prodesse, Inc. was submitted stating that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review.

6. A Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure.

The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the

{3}

Page 4 of 4

design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device.